Healthcare, Financials Dec 04, 2021 09:39 AM (GMT+8) · EqualOcean
Recently, Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd. completed a + round of financing of nearly 100 million yuan. This round is led by Jingwei venture capital, and also followed by Huicheng, Shanlan capital and Yuanhui venture capital. Kangyuan Bochuang is an innovative technology platform company focusing on new drug R & D services. It has built the industry's largest genetic engineering cell bank, established mature GPCR antibody discovery technology, and developed platforms such as nano antibody, bispecific antibody, gene editing mouse, defective CHO cell expression system, etc.